Emerging CAR-Treg and regulatory T cell therapies for inflammatory bowel diseases: a systematic review of a new era of treatment
Fabio Suarez-Trujillo, Theodore S. Steiner, Javier P. Gisbert, María Chaparro · 2026
Read Emerging CAR-Treg and regulatory T cell therapies for inflammatory bowel diseases: a systematic review of a new era of treatment by Fabio Suarez-Trujillo, Theodore S. Steiner, Javier P. Gisbert, María Chaparro (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13582436.txt.
Description
Fabio Suarez-Trujillo and co-authors review engineered regulatory T cell therapies for inflammatory bowel disease in this 2026 paper. The disease is a chronic, immune-driven attack on the gut lining. Many patients never reach or hold remission on current drugs. Regulatory T cells are the immune system's own brakes. Lab-made versions, some fitted with a targeting receptor, aim to calm the gut directly. The review weighs the reasoning and the evidence so far.
Animal and early lab studies support the idea and its feasibility. Human evidence is still thin, the authors stress. Such cell therapies are a distinct path from standard drugs. Hard-to-treat patients are the hoped-for first beneficiaries. Safety and staying power are the open questions. The paper surveys a field its title calls a new era, with caution.
Catalog record
| CREATOR | Fabio Suarez-Trujillo, Theodore S. Steiner, Javier P. Gisbert, María Chaparro |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |